entertainment -WSS

entertainment

author：fashion 2025-10-02 19:39:02 - browse：27

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Cancer researcher Catriona Jamieson is sending tumors into space

hotspot

WSS

Cholera vaccine supply gets boost as demand surges globally

H5N1 bird flu found in pasteurized milk: what we know

Bird flu in milk supply is likely coming from asymptomatic cows

UnitedHealth financials solid despite Change Healthcare cyberattack

Medicare Advantage proposed rates disappoint insurers

To avoid data mishandling cases, universities eye AI and other tools

leisure time

entertainment

focus

How one medical school became remarkably diverse

Key House Republican on health care plans exit from Congress

Walensky prepares to leave CDC — and Congress — behind

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What we’ve learned from the Aduhelm mess

Medical records are filled with copy

Bird flu in milk supply is likely coming from asymptomatic cows

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

After traumatic brain injury, life support decisions can use more time

entertainment

Why rehabilitation engineers need to center patients in their research

For Medicare Advantage, Democrats want stronger protections around AI

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

UnitedHealth financials solid despite Change Healthcare cyberattack

Private equity deals in Medicare Advantage declines

Cell therapy fails to slow type 1 diabetes, but safety is established

hotspot

focus

focus

hotspot